Power Doppler Imaging and prostate cancer: Optional or necessary technique?;Écho-Doppler et cancer de la prostate: Option ou nécessité?

Journal de Radiologie

Volumn 87, Issue 9, 2006, Pages 1063-1072

  Sauvain, J L ^a   Palascak, P ^b   Nader, N ^b   Gomez, W ^b   Bloqueau, Ph ^a   Bremon, J M ^a   Jung, L ^a   Maniere, Ph ^a   Papavero, R ^a  

^a Centre d'Imagerie Médicale

^b Service d'Urologie   (France)

Author keywords

Doppler and power Doppler imaging; Prostate, cancer, ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; BIOPSY; BLOOD; DOPPLER FLOWMETRY; ECHOGRAPHY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, DOPPLER;

EID: 33747834709     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0221-0363(06)74128-2     Document Type: Article

References (39)

1. Bauvin E, Remontet L, Grosclaude P, réseau FRANCIM, Cepidc. Incidence de la mortalité du cancer de la prostate en France/Tendances évolutives entre 1978 et 2000. Prog Urol 2003;13:1334-9.
2. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-years follow up of the 1988 Quebec prospective randomised controlled trial. Prostate 2004;59:311-8.
3. Neal DE, Donovan JL. Prostate cancer: to screen or not to screen? Lancet Oncol 2000;1:17-24.
4. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate specific antigen screening: lessons from US prostate cancer incidence trends. J Natl cancer Inst 2002;94:981-90.
5. Draisma G, Boer R, Otto SJ, Van Der Cruijsen IW, Damhuis RA, Schroder FH, De Koning HJ. Lead times and overdetection due to prostate antigen screening: estimates from the European Randomized study of screening for prostate cancer. J Natl cancer Inst 2003;95:868-78.
6. Stamey TA, Cadwell M, Mcneal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
7. Niemann TR, Bahnson RR. Extended sector biopsy for detection of carcinoma of the prostate. Urol Oncol 2001;6:91-3.
8. Djavan B, Remzi M, Schulmann C, Marberger M, Zlotta A. Repeat prostate biopsy: who, how and when? A review. Eur Urol 2002;42:93.
9. Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when? An Update. Can J Urol 2005;12:44-8.
10. Cornud F, Peyromaure M, Veillefond A, Zerbib M, Flam T, Chevrot A. Comment nous faisons une biopsie de prostate. Feuillets de radiologie 2005;45:297-307.
11. Stamey TA, Yang N, Hay AR, Mc Neal JE. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987;317:909-16.
12. Kattan MW, Zelefsky MJ, Kupelian PA. Pretreatment nomogramm for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J clin Oncol 2000;18:3352-9.
13. Resnick NI, Willard JW, Boyce WH. Ultrasonic evaluation oi the prostatic nodule. J Urol 1981;120:86-9.
14. Rifkin M, Sudakoff G, Alexander A. Prostate: techniques, results and potential applications of color Doppler US scanning. Radiology 1993;186:509-13.
15. Kelly I, Lees W, Rickards D. Prostate cancer and the role of color Doppler US. Radiology 1993;189:153-6.
16. Bree RL. The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997;49:31-4.
17. Ismail M, Petersen Ro, Alexander AA, Newschaffer C, Gomella Lg. Color Doppler Imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 1997;50:906-12.
18. Lavoipierre AM, Snow RM, Frydenberg M et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol 1998;171:205-10.
19. Cornud F, Belin X, Piron D et al. Color Doppler guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for non palpable lesions. Urology 1997;49:709-15.
20. Gohji K, Morisue K, Kizaki T, Fujii A. Correlation of transrectal ultrasound imaging and the results of systematic biopsy with pathological examination of radical prostatectomy specimens. Br J Urol 1995;75:758-65.
21. Newmann JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histological correlation of each biopsy site. Radiology 1995;195:86-90.
22. Halpern EJ, Strup SE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol 2000;174:623-7.
23. Sauvain JL, Palascak P, Bourscheid D et al. Value of Power Doppler and 3D vascular sonography as a method for the diagnosis and staging of prostate cancer. Eur Urol 2003;44:21-31.
24. Cornud F, Hamida K, Flam T et al. Endorectal color Doppler Sonography and endorectal MR, imaging feature of non palpable prostate cancer: correlation with radical prostatectomy findings. AJR Am J Roentgenol 2000;175:1161-8.
25. Hodge KK, Mcneal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-5.
26. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long term follow up. J Urol 1993;150:135-41.
27. Esptein JI, Chan W, Sokoll LJ, Walsch PC, Akingba G, Carter HB. Non palpable stage Tlc prostate cancer: prediction of insignificant disease using free/total antigen levels and biopsy findings. J Urol 1998;160:2407-11.
28. Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: a potential useful alternative to mean frequency based color Doppler US. Radiology 1994;190:853-6.
29. Leventis AK, Shariat SF, Utsunomiya T, Slavim KT. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. Prostate 2001;46:281-8.
30. Thompson IM, Pauler DK, Goodmann PJ et al. Prevalence of prostate cancer among men with a prostate specific antigen level < or =4,0ng per milliliter. N Engl J med 2004;350:2239-46.
31. Partin AW, Mangold LA, Lann DH, Walsch PC, Esptein JL, Pearson JD. Contemporary update of prostate staging nomogramm (Partin tables) of the new millenium. Urology 2001;58:843-8.
32. Remzi M, Dobrovits M, Reissigl A et al. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy. Eur Urol 2004:46:451-6.
33. Okihara K, Kojima M, Nakanouchi I, Okada K, Miki T. Transrectal power Doppler imaging in the detection of prostate cancer. BJU Int 2000;85:1053-7.
34. Brawer Mk, Deering Re, Brown M. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 1994;73:678-87.
35. Weidner N, Caroll Pr, Flax J, Folkmann J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 1993;143:401-9.
36. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Rowley Dr. Reactive stroma in human Prostate cancer. Induction of myofibroblast phenotype and extra matrix remodeling. Clin Cancer Res 2002;8:2912-23.
37. Allan RW, Sanderson H, Esptein JI. Correlation of minute (0.5mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimens: role of prostate antigen density. J Urol 2003,170:370-2.
38. Zackrisson B, Aus G, Bergdahl S et al. The risk of finding focal cancer (less than 3mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004;171:1500-3.
39. Hara N, Kasahara T, Kawasaki T et al. Frequency of PSA-mRNA- bearing cells in the peripheral blood of patients after prostate biopsy. Br J Cancer 2001;85:557-62.